Analysis of the Expression and Prognostic Value of SIRTs in Hepatocellular Carcinoma
DOI: https://doi.org/10.2147/ijgm.s460549
IF: 2.145
2024-06-07
International Journal of General Medicine
Abstract:Chuang Qin, 1 Xiaofei Ye, 1 Hongliang Luo, 1 Hu Jin, 1 Qiang Liu, 1 Jiangfa Li 2 1 Hepatobiliary Surgery, Liuzhou People's Hospital Affiliated to Guangxi Medical University, Liuzhou City, Guangxi, People's Republic of China; 2 Hepatobiliary Surgery, The Affiliated Hospital of Guilin Medical University, Guilin City, Guangxi, People's Republic of China Correspondence: Jiangfa Li, Hepatobiliary Surgery, The Affiliated Hospital of Guilin Medical University, No. 15, Lequn Road,Xiufeng District, Guilin City, Guangxi, 541001, People's Republic of China, Email Purpose: This study contributes to the evolving understanding of the pivotal involvement of Sirtuins (SIRTs) in various human cancers, with a particular focus on elucidating their expression patterns and clinical relevance within the context of hepatocellular carcinoma (HCC). The investigation involves a comprehensive analysis of mRNA expression and prognostic implications associated with distinct SIRTs in HCC. Patients and Methods: Initial data pertaining to SIRT expression in HCC patients were collated from publicly accessible databases. Subsequently, the expression levels of select members of the SIRT family were validated using clinicopathological specimens from HCC patients. Additionally, HCC tissue microarray was employed to scrutinize the correlation between SIRT7 expression and HCC prognosis. Results: The findings indicated a substantial upregulation of SIRT2, SIRT3, SIRT4, SIRT6, and SIRT7 in HCC tissues. Survival analysis underscored a pronounced association between elevated mRNA levels of SIRT3, SIRT6, and SIRT7 and an adverse prognosis for HCC patients. Particularly, SIRT7 emerged as a potential independent risk factor for poor prognosis in HCC patients. Examination of the HCC tissue microarray revealed heightened expression of SIRT7 in 68 cases (54.8%) of HCC tissues. Multivariate analysis established high SIRT7 expression as an independent risk factor for diminished Disease-Free Survival (DFS) and Overall Survival (OS) in HCC patients. Conclusion: The aberrant expression of SIRT7 presents itself may be as a novel biomarker for predicting the prognosis of HCC patients. Keywords: HCC, microarray, prognosis, SIRT7, survivor The World Health Organization predicts that liver cancer will claim the lives of over one million individuals by 2030, with hepatocellular carcinoma (HCC) emerging as the predominant variant. 1 Despite notable strides in the prevention, detection, diagnosis, and treatment of HCC in recent years, patient prognosis remains suboptimal due to the intricate pathological mechanisms and the proclivity of HCC for invasion and metastasis. Currently, there exists a deficiency in effective biomarkers for early HCC diagnosis and prognosis prediction. Consequently, the identification of novel molecular biomarkers for the diagnosis, treatment, and prognosis of HCC holds significant clinical importance. Silent mating type information regulation 2 homologs (sirtuins) represent NAD+-dependent histone deacetylases with regulatory roles in diverse cellular processes, including proliferation, apoptosis, and metabolism. 2–4 The expression patterns of sirtuin (SIRT) genes vary across different cancer types. 3 SIRT1 and SIRT3 may exhibit either upregulation or downregulation depending on the cancer type, functioning as oncogenes in colorectal and oral cancers or as tumor suppressor genes in bladder, breast, and anterior adenocarcinoma. 5–8 Conversely, SIRT2 and SIRT4 are deemed tumor suppressors, experiencing downregulation in glioma, HCC, bladder, stomach, and lung cancers. 9,10 While the role of SIRT5 in tumorigenesis remains poorly understood, its overexpression has been noted in colorectal and non-small cell lung cancers (NSCLC). 11,12 SIRT6 is downregulated in several cancers, including colorectal cancer, but is overexpressed in breast adenocarcinoma and NSCLC. 11,12 Current investigations reveal that SIRT7 is highly expressed in breast, ovarian, and kidney cancers, exerting cancer-promoting effects. 13–15 Conversely, it exhibits low expression levels in pancreatic cancer and head and neck squamous cell carcinoma, where it exerts tumor-suppressive effects. 6,16 These studies suggest that the expression profiles of SIRT family members in different cancer types may be tissue-specific, rendering the exploration of SIRT family members in various tumors a subject of ongoing controversy. In this context, we conducted a review of studies related to SIRTs, revealing a paucity of research on SIRTs in HCC, particularly in relation to clinicopathological features and prognosis in HCC patients. Consequent -Abstract Truncated-
medicine, general & internal